我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

紫杉醇微孔载药支架与进口雷帕霉素药物洗脱支架治疗冠心病的临床效果比较(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第3期
页码:
358-360,369
栏目:
临床研究
出版日期:
2012-06-25

文章信息/Info

Title:
Comparison of clinical outcomes of paclitaxel-loaded microporous stents vs. imported sirolimus-eluting stents for treatment of coronary heart disease
作者:
李 涛金 鹏李光南温 亮李佳欣任喜君李学奇
(哈尔滨医科大学第四附属院心内科六病房,黑龙江 哈尔滨 150001)
Author(s):
LI Tao JIN Peng LI Guang-nan WEN Liang LI Jia-xin REN Xi-jun LI Xue-qi
(Department of Internal Medicine, Fourth Affiliated Hospital, Harbin Medical University, Harbin 150001, Heilongjiang, China)
关键词:
紫杉醇微孔载药支架雷帕霉素药物洗脱支架临床疗效
Keywords:
paclitaxel-loaded microporous stent sirolimus-eluting stent clinical outcomes
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:比较紫杉醇微孔载药支架和进口雷帕霉素药物洗脱支架在经皮冠状动脉介入治疗中的临床疗效。方法: 筛选73例行经皮冠状动脉介入治疗术的冠心病患者,随机分为两组,紫杉醇微孔载药支架组(紫杉醇组,35例)和进口雷帕霉素药物洗脱支架组(雷帕霉素组,38例)。支架植入术后6个月复查冠状动脉造影(CAG)。随访6个月,对比两组支架内血栓形成、主要心血管不良事件(包括心源性死亡、非致死性心肌梗死、靶病变血运重建)和支架内再狭窄发生率。结果: 随访6个月,两组均未出现急性、亚急性和晚期支架内血栓形成、非致死性心肌梗死和心源性死亡。心绞痛、支架内再狭窄和靶病变血运重建发生率均无统计学差异。结论: 紫杉醇微孔载药支架与进口雷帕霉素药物洗脱支架在治疗冠状动脉简单病变时具有相同的近、中期临床疗效和安全性。
Abstract:
AIM:To compare the outcomes of paclitaxel-loaded microporous stents and imported sirolimus-eluting stents in the treatment of patients undergoing percutaneous coronary intervention (PCI). METHODS: Seventy-three patients who underwent PCI were randomly divided into two groups: 35 patients with paclitaxel-loaded microporous stent (paclitaxel stents) and 38 patients with imported sirolimus-eluting stents (sirolimus group). Coronary artery angiography (CAG) was performed in all patients after a 6-month follow-up period. The incidence of major adverse cardiac events (MACEs) including cardiac death, myocardial infarction and target lesion revascularization and in-stent restenosis rate were compared. RESULTS: During a 6-month follow-up, there were no acute, subacute, or late stent thromboses, nonlethal myocardial infarction or cardiac deaths in the two groups. Differences in angina, in-stent restenosis and target lesion revascularization were not statistically significant between groups. CONCLUSION: Paclitaxel-loaded microporous stents have the same clinical effects and safety as imported sirolimus-eluting stents for coronary artery disease in clinical outcomes in the short- and medium-term. Moreover, the cost-effectiveness ratio of paclitaxel-loaded microporous stents is higher.

参考文献/References

[1]Mraks AR.Sirolimus for the prevention of in-stent restenosis in a coronary artery[J].N Engl J Med, 2003,349(14):1307-1309.

[2]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.

[3]Cutlip DE,Windecker S,Mehran R,et al.Academic Research Consortium.Clinical end points in coronary stent trials:a case for standardized definitions[J].Circulation,2007,115(17):2344-2351.

[4]Losordo DW,Isner JM,Diaz-Sandoval LJ.Endothelial recovery:thenext target in restenosis prevention[J].Circulation,2003,107(21):2635-2637.

[5]Iijima R,Ikari Y,Amiya E,et al.The impact of metallic allergy on stent implantation:metal allergy and recurrence of in-stent retenosis[J].Int J Cardiol,2005,104(3):319-325.

[6]Dietz U,Dauer C,Lambertz H.Combining short implantation and drug-eluting stenting for routine use yields a low restenosis rate[J].Curr Control Trials Cardiovasc Med,2005,6:18.

[7]赵 惠,肖 虹.冠状动脉洗脱支架的特点及其临床应用[J].中国组织工程研究与临床康复,2009,13(38):7575-7578.

[8]Serruys PW,Regar E,Carter AJ.Rapamycin eluting stent:the onset of a new era in interventional cardiology[J].Heart,2002,87(4):305-307.

[9]倪 钧,沈卫峰,张建盛,等.Firebird药物洗脱支架治疗冠状动脉原发病变[J].介入放射学杂志,2004,13(5):396-398.

[10]杨永祥,王 萍.冠状血管内生物可吸收支架的最新进展[J].中国心血管病研究,2007,5(10):789-791.

[11]王春宇,高润霖,程树林,等.聚-乳酸-乙醇酸涂层冠脉支架的生物相容性实验研究[J].中华心血管病杂志,2003,31(7):528-531.

[12]Mcfadden EP,Stabile E,Regar E,et al. Late thrombosis in drug-eluting coronary after discontinuation of antiplatelet therapy[J].Lancet, 2004,364(9444):1519-1521.

备注/Memo

备注/Memo:
收稿日期:2011-10-11.通讯作者:李学奇,主任医师,主要从事冠脉介入及心脏电生理的研究Email:lixueqi@medmail.com 作者简介:李涛,硕士生 Email:baobudong@126.com
更新日期/Last Update: 2012-05-02